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Abstract
Background: Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the metabolism
of folate. The non-synonymous single nucleotide polymorphism (nsSNP), C677T (Ala>Val,
rs1801133), has been verified to impair enzyme activity. The association with cancer susceptibility,
including hepatocellular carcinoma (HCC), has also been widely studied. The results, however,
were inconsistent. To shed light on the influence of MTHFR C677T polymorphism on HCC, a
meta-analysis was conducted.
Methods: The meta-analysis of C677T consisted of 10 studies (1814 cases/2862 controls). The
association was measured by using random-effect (RE) or fixed-effect (FE) odds ratio (OR)
combined with 95% confidence intervals (CIs) according to the studies' heterogeneity.
Results: Using genetic model analysis, C677T polymorphism was found to increase the risk of
HCC in a complete overdominant model, which indicates that heterozygotes CT are at a lesser
risk of HCC than either homozygotes CC or TT. Meta-analyses of the 10 studies showed that the
TT genotype increased the risk of HCC as compared to the CT genotype: FE OR was 1.20 (95%CI:
1.00-1.45, p for heterogeneity = 0.21). When subgroup analysis was done between the HCC cases
and the chronic liver disease (CLD) patients of four studies, meta-analysis showed that individuals
with the TT genotype had increased HCC risk compared with those with the CT genotype: FE OR
(TT vs. CT) reached 1.81 (1.22-2.71, p for heterogeneity = 0.25). Meanwhile, the C677T
polymorphism also increased HCC risk in a recessive model when cases were compared to CLD
patients of four studies: RE OR reached 1.85 (95%CI: 1.00-3.42, p for heterogeneity = 0.06).
Overall, there was some extent heterogeneity when analyses were performed in various models.
There was no publication bias.
Conclusion: MTHFR C677T polymorphism increased the risk of HCC in an overdominant model,
and might be a risk factor for HCC occurrence, especially in CLD patients. The association
warranted further studies.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in the world and the third leading cause of
cancer deaths [1]. Genetic variation has been postulated
to influence the variable risk for HCC observed both
within and across populations. Because the liver is the
main metabolizing organ and plays an important role in
the detoxification or activation of carcinogens, metaboliz-
ing enzyme genes have become the best HCC candidate
genes. These metabolizing enzymes include cytochrome
P450 2E1 (CYP2E1), UDP-glucuronosyltransferase1A7
(UGT1A7), N-acetyltransferase (NAT2), manganese
superoxide dismutase (MnSOD), and alcohol dehydroge-
nase-2 (ALDH2), among others [2-6].
Methylenetetrahydrofolate reductase (MTHFR) is a key
enzyme in the metabolism of folate [7]. According to Ent-
rez Gene, MTHFR (gene ID: 4524) maps on chromosome
1 at 1p36.3. It covers 21.20 kb, from 11789564 to
11768370 (NCBI 36, March 2006), on the reverse strand.
The gene product is a 77 kD protein. Together with other
enzymes, MTHFR plays a central role in folate metabolism
by irreversibly catalyzing the conversion of 5,10-methyl-
enetetrahydrofolate (5,10-methylene-THF) to 5-methyl-
tetrahydrofolate (5-methylene-THF), the primary
circulating form of folate and a cosubstrate for homo-
cysteine methylation to methionine. In humans, folate
plays a fundamental role in providing methyl groups for
de novo deoxynucleotide synthesis and intracellular
methylation reactions. One non-synonymous single
nucleotide polymorphism (nsSNP) of MTHFR, C677T
(Ala>Val, rs1801133), has been proven to impair enzyme
activity [8]. From three nsSNP function prediction Web
software programs, namely, SIFT http://sift.jcvi.org[9],
Polyphen http://coot.embl.de/PolyPhen[10], and
SNPs3D http://www.snps3D.org[11], 10 nsSNPs that pos-
sibly damage protein function were detected. The three
software programs simultaneously predicted that C677T
(rs1801133), which changes the amino acid Ala to Val,
damages the protein function. The relationship of C677T
and cancers has been widely studied. C677T was reported
to be associated with prostate cancer [12], breast cancer
[13], colorectal cancer [14], stomach cancer [15], bladder
cancer [16], esophageal cancer [17], and leukemia [18],
among others.
A number of studies have explored the correlation of
MTHFR C677T polymorphism and HCC, but the results
are controversial [19-26]. To shed light on the influence of
MTHFR C677T polymorphism on HCC, a meta-analysis
was carried out.
Methods
Study identification and selection
Eligible studies were identified by searching the database
of PubMed, ISI Web of Knowledge, Elsevier ScienceDirect,
and HuGE Navigator Web server http://www.hugenaviga
tor.net[27] for relevant reports in English published
before May 2009 using the following search terms:
"MTHFR" or "methylenetetrahydrofolate reductase" and
"liver cancer" or "hepatocellular carcinoma." The reports
and dissection database published in the Chinese Bio-
medical Database (CBM), China National Knowledge
Infrastructure (CNKI), and Wan Fang (Chinese) database
were also searched to collect articles of case-control stud-
ies or cohort studies on associations between MTHFR pol-
ymorphisms and susceptibility to HCC before May 2009.
Studies were selected if there were available data for
MTHFR C677T polymorphism with the risk of HCC using
a case-control or cohort design. The reference lists of
retrieved articles were also reviewed to identify additional
articles missed by the above search. Studies that deter-
mined the distribution of the C677T genotype in cases
with HCC diagnosed by histopathological biopsy or by
elevated α-fetoprotein (AFP) and distinct iconography
changes (CT, MRI, and B ultrasonography), and in con-
trols free of cancer were eligible for inclusion in the meta-
analysis. Review articles, case-only articles, and repeated
literatures were excluded.
MTHFR genotyping methods
Seven articles (which included eight studies) [19-22,24-
26] and one unpublished Chinese research used extra
blood samples to extract genome DNA, of which seven
studies used polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP) to genotype, and
one article [25] (which contained two studies) used fluor-
ogenic 5'-nuclease assay (TaqMan Assay) to genotype.
One study [23] published in Chinese extracted DNA from
HCC tumor tissue and peritumoral tissue for genotyping
using the PCR-RFLP method.
Data extraction and synthesis
The following information was extracted from each study:
first author's surname, year of publication, ethnicity of
study population, country where the study was con-
ducted, genotyping method, and the number of cases and
controls for each C677T genotype. When specific results
were not directly reported, available tabular data were
used to calculate them.
Statistical methods
In order to compare the odds ratio (OR) on the same base-
line, crude OR was used for the meta-analysis. Following
the genetic model analysis methods suggested by Thak-
kinstian A et al. [28], the wild-type allele was first set as A
and the variant allele as B. Then meta-analysis examined
the association for the allele contrast BB vs. AA (OR1), AB
vs. AA (OR2), and BB vs. AB (OR3). Next, the best genetic
model was determined according to the relation of the
values of OR1, OR2, and OR3. If OR1 = OR3 ≠ 1 and OR2
= 1, then a recessive model is suggested. If OR1 = OR2 ≠ 1Page 2 of 8
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= 1, OR2 = 1, and OR3 ≠ 1, then a complete overdominant
model is suggested. If OR1>R2>1 and OR1>OR3>1 (or
OR1<OR2<1 and OR1<OR3<1), then a codominant
model is suggested. The effect of association was indicated
as crude OR with the corresponding 95%CI. The pooled
OR was estimated using the fixed-effect (FE) model or the
random-effect (RE) (DerSimonian and Laird) model [29].
The heterogeneity between studies was tested using Q sta-
tistic [30]. If p < 0.10, the heterogeneity was considered
statistically significant, and then the RE model was used.
Heterogeneity was quantified using the I2metric, which is
independent of the number of studies in the meta-analy-
sis (I2<25%, no heterogeneity; I2 = 25-50%, moderate het-
erogeneity; I2>50%, large or extreme heterogeneity) [31].
A cumulative meta-analysis was carried out to evaluate the
trend of pooled OR. The potential publication bias was
tested using the Egger regression test asymmetry and
Begg's test for funnel plot. The distribution of the geno-
types in the control group was tested for Hardy-Weinberg
equilibrium using a goodness-of-fit chi-square test.
All analyses above were conducted using STATA, version
10.0, software (Stata Corp., College Station, Texas). All p
values were two sided. A p value less than 0.05 was con-
sidered statistically significant.
The false positive report probability (FPRP), the probabil-
ity of no true association between a genetic variant and
disease given a statistically significant finding, depends
not only on the observed p value but also on both the
prior probability that the association between the genetic
variant and the disease is real and the statistical power of
the test. An Excel spreadsheet to calculate FPRP is included
with the online material (see http://jncicancerspec
trum.oupjournals.org/jnci/content/vol96/issue6) [32].
The statistical power was calculated using the PS software
http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/
PowerSampleSize[33,34]. Given that the gene mutation
was regarded as causal, we used population-attributable
risk (PAR) to refer to the proportion of disease risk in a
population that can be attributed to the causal effects of
the risk gene. PAR can be assessed by using the formula
[35]: PAR (%) = p(OR-1)/(p(OR-1)+1) × 100%, where p
is the proportion of the individuals exposed to risk gene
in the general population, and OR is the pooled OR when
cases and controls were compared in the risk model.
Results
Eligible studies
All together, eight articles (which included nine studies)
published in English and one Chinese graduate paper
(not in the list of references) met the inclusion criteria.
One article [25] contained two different ethnic popula-
tions, so it was regarded as two studies. In total, ten stud-
ies (1814 cases/2862 controls) examined C677T
polymorphism were included in the meta-analysis (Table
1).
All studies were published between 2004 and April 2009.
In all studies, the cases were histologically confirmed or
diagnosed by elevated AFP and distinct iconography
changes (CT, MRI, and B ultrasonography). The controls
were free of cancer. All ten studies reported the use of
healthy controls or non-liver disease, non-cancer patients
as controls. Four studies [19,24,26,36], on the other hand,
included chronic liver disease (CLD) patients as controls.
CLD patients were mainly liver cirrhosis (LC) patients.
Liver cirrhosis was either histologically proved or diag-
nosed on concordant clinical, biological, and morpholog-
ical criteria.
Studies were conducted in various populations of differ-
ent ethnicity: Five studies were conducted in populations
of Asian ethnicity [20,22,23,25] (one Chinese paper not
in the list of references), and another five studies involved
Europeans or Americans [19,21,24-26]. The genotype dis-
Table 1: Description of the studies included in the meta-analysis of the relationship of MTHFR C677T and HCC
Author Year Country Case/control Source of controls Cases controls
CC CT TT CC CT TT
Fabris 2009 Italy 65/236 Population and hospital 22 30 13 111 195 77
DÁmico 2009 Italy 94/308 Population and hospital 30 37 27 133 131 44
Kwak 2008 Korea 96/201 population 32 46 18 64 106 31
Yuan 2007 American 118/209 population 53 51 14 80 99 30
Yuan 2007 China 247/248 hospital 159 71 17 156 74 18
Mu 2007 China 194/391 population 50 114 30 135 199 57
Zhu 2006 China 508/543 hospital 172 226 110 173 268 102
Ventura 2005 Italy 22/162 Population and hospital 8 5 9 94 48 20
Yang 2005 China 322/185 population 229 80 13 131 46 8
Saffroy 2004 France 148/232 Population and hospital 67 69 12 92 114 26Page 3 of 8
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not conform to the HWE equilibrium (p = 0.03 and 0.001,
respectively).
Meta-analysis results
In all 10 studies, the T allele frequency of C677T was 0.37
in the control group (2106/5724) and was 0.35 in the case
group (1255/3628). The T allele was more likely found in
the control groups (p = 0.03). The T frequency in the Euro-
pean controls of five studies was 0.38 (981/2588), and
that in the Asian controls of five studies was 0.36 (1125/
3136). This showed that there is no inter-ethnicity differ-
ence in minor allele frequency (p = 0.11).
The genetic model analysis of 10 studies (including all
controls) showed pooled OR1 (TT/CC) = 1, pooled OR2
(TC/CC) = 1, and pooled OR3 (TT/CT)>1, indicating that
a complete overdominant model was applicable. FE OR3
reached 1.20 (95%CI: 1.00-1.45, p for heterogeneity =
0.21) (Figure 1), showing that an overdominantly acting
protective allele was applicable, that is, heterozygotes are
at a lesser risk of HCC than either homozygotes (CC or
TT). However, when two studies [25,26] that were not in
agreement with the HWE equilibrium were excluded, the
association was no longer significant (pooled OR3 = 1.18,
95%CI: 0.97-1.43, p for heterogeneity = 0.39), suggesting
that the result was not stable.
The meta-analysis results under three conditions, namely,
dominant model, recessive model, and allele frequency
contrast (T vs. C), including 10 studies, all failed to reach
statistic significance. To illustrate, RE OR reached 1.02
(95%CI: 0.85-1.23, p for heterogeneity = 0.07) for the
dominant model, 1.22 (95%CI: 0.92-1.61, p for heteroge-
neity = 0.02) for the recessive model, and 1.08 (95%CI:
0.92-1.27, p for heterogeneity = 0.00) for the T vs. C case
(Table 2). The meta-regression and sensitivity analyses
found that two studies [21,26] were the main sources of
heterogeneity. Therefore, heterogeneity was reduced sig-
nificantly after excluding these two studies, without sub-
stantially altering the meta-analysis results.
Stratified analyses were conducted according to the con-
trol collection (CLD patients or non-liver disease con-
trols) and regions (Europe or Asia). The meta-analysis of
four studies (including 329 HCC cases and 625 CLD
patients) showed a positive association of 677TT with
HCC in CLD patients: pooled FE OR3 (TT/CT) reached
1.81 (95%CI: 1.22-2.71, p for heterogeneity = 0.25) (Fig-
ure 2), indicating that a complete overdominant model
was still applicable. Meanwhile, the recessive model RE
OR of four studies reached 1.85 (95%CI: 1.00-3.42, p for
heterogeneity = 0.06). FE OR of four studies reached 0.75
(95%CI: 0.57-0.99, p for heterogeneity = 0.92) as CT het-
erozygotes was compared with (CC+TT) between cases
and CLD patients of four studies. Table 3 showed the
results of the meta-analysis of four studies when CLD
patients were compared with the cases. It is worth noting
that all four studies including CLD patients as controls
were from European populations, so the result was only
observed from European CLD patients.
Subgroup meta-analysis of (1) the comparison between
the healthy controls and HCC cases of 10 studies; (2) five
studies of European populations and (3) five studies of
Asian populations all showed that 677T allele had a non-
significantly increased risk of HCC and had a non-signifi-
cant trend of overdominant model to HCC occurrence
(detailed data not shown).
Publication bias analyses of 10 studies including all con-
trols and four subgroup studies that used CLD controls
both showed no publication bias: Egger's p reached 0.25-
0.84 under various models.
However, the sensitivity analysis showed that the associa-
tion between C677T and HCC (TT vs. CT) of 10 studies
(including all cases and controls) was vulnerable: when
someone studies was omitted at a time, the 95%CI of the
OR3 (TT/CT) model would include 1.0 (Figure 3). Fur-
ther, the sensitivity analysis showed that the association
between C677T and HCC (TT vs. CT) was also vulnerable
when CLD patients were used as controls (Figure 4). This
Forest plot of the odds ratios (ORs) and 95% confidence intervals (CIs) of studies on the association between HCC and the MTHFR C677T polymorphism (TT vs. CT) of ten studies (including all controls)igur 1
Forest plot of the odds ratios (ORs) and 95% confi-
dence intervals (CIs) of studies on the association 
between HCC and the MTHFR C677T polymor-
phism (TT vs. CT) of ten studies (including all con-
trols). On the left, the first author of the study is followed 
by the publication year in parentheses. The size of the black 
box corresponding to each study is proportional to the sam-
ple size. The horizontal line shows the corresponding 95%CI 
of the OR. The combined estimate is based on a fixed-effects 
model shown by the diamond. The solid vertical line repre-
sents the null result.Page 4 of 8
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shown).
When meta-analysis was performed in four studies using
CLD patients as controls, the cumulative meta-analysis of
the recessive model and the OR3 (TT/CT) of C677T
showed a stable increased risk trend of HCC occurrence as
evidences accumulated (figure not shown).
Because most HCC occurred in LC patients, MTHFR
C677T polymorphism may have important clinical val-
ues. We further analyzed the reliability of the result in
other ways below.
In four studies including CLD patients (mainly LC
patients) as controls, there were 329 HCC cases and 625
patients. The proportion of CLD patients with TT or CC
genotype was 0.53, and FE OR (TT+CC vs. CT) was 1.33.
Then, the statistical power calculated by using the PS soft-
ware was 0.55.
A statistically significant association (p < 0.05) can be fur-
ther evaluated by estimating the false-positive report
probability (FPRP) [32] at a given prior probability and
statistical power. If the prior probability (incidence of
HCC among LC patients) was set to 0.30, and OR = 1.33
(95%CI: 1.01-1.76) (TT+CC vs. CT), then FPRP equaled
0.18(<0.20), indicating that the association was notewor-
thy.
In CLD patients, PAR can be assessed by using the formula
[35]: PAR (%) = p(OR-1)/(p(OR-1)+1) × 100%, where p
is the proportion of the individuals exposed to risk gene
(proportion of CC and TT genotype was 0.53 in the CLD
patients), and OR is the pooled OR when cases and con-
trols were compared in the risk model (OR = 1.33). Then,
PAR was 14.88% (95%CI: 1.22%-28.54%).
Discussion
HCC is a complex disease that involves multistep, multi-
gene, and gene-environment interactions. To date, the
results found on the association of MTHFR C677T poly-
morphism with HCC are inconsistent, and there is still no
meta-analysis study that has successfully established the
relationship of MTHFR C677T polymorphism and HCC.
MTHFR plays a central role in folate metabolism [7]. Indi-
viduals who are heterozygous (CT) or homozygous (TT)
for MTHFR C677T polymorphism have an in vitro
enzyme activity that is 65% or 30% of that of wild-type
homozygous (CC) individuals, respectively [8]. Methyl-
ene-THF is involved in the conversion of deoxyuridylate
monophosphate (dUMP) to deoxythymidylate mono-
phosphate (dTMP). Low levels of 5,10-methylene-THF
would lead to an increased dUMP/dTMP ratio. In addi-
tion, increased incorporation of uracil into DNA in place
of thymine may increase the chance of point mutations
and DNA/chromosome breakage. A less active MTHFR
would lead to an accumulation of 5,10-methylene-THF;
thus, a lower dUMP/dTMP ratio may reduce cancer risk
[37]. Impaired MTHFR activity, on the other hand, might
influence cancer risk by the level of S-adenosyl-L-methio-
nine, the common donor of the methyl group that is nec-
essary for maintaining the methylation patterns in DNA.
The MTHFR of low activity leads to lower S-adenosyl-L-
Table 2: Meta-analysis results of the association of C677T polymorphisms and HCC of 10 studies.
Genetic model OR 95%CI p for herterogeneity I2 Egger's p
TT/CC (OR1) 1.19 0.86-1.65 0.01 0.58 0.84
CT/CC (OR2) 0.96 0.84-1.10 0.42 0.02 0.71
TT/CT (OR3) 1.20 1.00-1.45 0.21 0.25 0.84
(TT+CT)/CC 1.02 0.85-1.23 0.07 0.43 0.32
TT/(CC+CT) 1.22 0.92-1.61 0.02 0.53 0.84
CT/(CC+TT) 0.92 0.81-1.05 0.65 0 0.75
T/C 1.08 0.92-1.27 0.00 0.64 0.37
Forest plot of the ORs and 95%CIs of studies on the associa-ti n between HCC and MTHFR C677T polym rp ism (TT vs. CT) h t  LD controls were compared with the HC  cases four stu iesigur 2
Forest plot of the ORs and 95%CIs of studies on the 
association between HCC and MTHFR C677T poly-
morphism (TT vs. CT) when the CLD controls were 
compared with the HCC cases of four studies. The 
size of the black box corresponding to each study is propor-
tional to the sample size. The horizontal line shows the cor-
responding 95%CI of the OR. The combined estimate is 
based on a fixed-effects model shown by the diamond.Page 5 of 8
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hypomethylation [38] and would be expected to increase
the risk of some cancers [39]. Therefore, we postulated
that MTHFR with a balanced or moderate activity (CT gen-
otype) could have the best protective role on cancer occur-
rence.
This meta-analysis of 10 studies (1814 cases/2862 con-
trols) showed that the CT heterozygotes of C677T poly-
morphism had the least risk of HCC, especially among
CLD controls, supporting this hypothesis. TT homozy-
gotes of MTHFR had the most distinct risk of HCC. The
meta-analysis in the current work was the first time which
used genetic analysis to explore the genetic model under-
lying hepatocarcinogenesis and found that MTHFR C677T
polymorphism increased the risk of HCC in a complete
overdominant model, suggesting it might be a risk factor
for HCC, especially in CLD patients. However, sensitivity
analysis showed that the association of C677T with HCC
was not robust. We thought that it was mainly because of
relatively small samples and low statistic power (power =
0.55). We further calculated FPRP and found it supported
the positive association with HCC in LC patients (FPRP <
0.2). Population-attributable risk (PAR) is a valuable
parameter to assess the influence of risk factors on disease
occurrence. PAR (14.88%, 95%CI: 1.22-28.54) among the
CLD patients indicated that the role of C677T polymor-
phism in HCC occurrence was modest.
It is worth noting that CLD patients were not used as con-
trols in five Asian studies, and there are no such data to
date. Therefore, an examination of this association in CLD
patients from Asian populations is urgently needed.
Several studies have reported the association between
MTHFR C677T polymorphism and various kinds of can-
cers, and a number of meta-analysis articles have summa-
rized the effects [12,40-48]. According to the results, the
677T allele increased the risk of breast cancer in premen-
opausal women, gastric cancer, bladder cancer, esopha-
geal cancer, multiple myeloma, and non-Hodgkin
lymphoma. In contrast, it decreased the risk of prostate
Table 3: Meta-analysis results of the association of C677T polymorphisms and HCC of 4 studies (including CLD controls)
Genetic model OR 95%CI p for herterogeneity I2 Egger's p
TT/CC (OR1) 1.72 0.84-3.52 0.04 0.64 0.69
CT/CC (OR2) 0.85 0.62-1.16 0.82 0 0.44
TT/CT (OR3) 1.81 1.22-2.71 0.25 0.28 0.71
(TT+CT)/CC 1.03 0.77-1.36 0.13 0.46 0.26
TT/(CC+CT) 1.85 1.00-3.42 0.06 0.60 0.78
CT/(CC+TT) 0.75 0.57-0.99 0.92 0 0.68
T/C 1.31 0.86-2.02 0.01 0.76 0.25
Sensitivity analysis: examining the influence of individual stud-ies of ten studies (TT vs. CT)Figure 3
Sensitivity analysis: examining the influence of indi-
vidual studies of ten studies (TT vs. CT). This figure 
shows the influence of each study on the meta-analysis, in 
which the meta-analysis estimates are computed by omitting 
one study at a time. By default, fixed-effects analyses are dis-
played.
Sensitivity analysis: examining the influence of individual stud-ies of four studie  which used CLD patients as controls (TT vs. CT)Figure 4
Sensitivity analysis: examining the influence of indi-
vidual studies of four studies which used CLD 
patients as controls (TT vs. CT). This figure shows the 
influence of each study on the meta-analysis, in which the 
meta-analysis estimates are computed by omitting one study 
at a time. By default, fixed-effects analyses are displayed.Page 6 of 8
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mia. The discrepancy of the role of C677T on different
cancers has yet to be elucidated. We postulate that it is the
interaction between MTHFR polymorphism and folate
and the balance of 5,10-methylene-THF and 5-methylene-
THF determine the susceptibility of different kinds of can-
cers. The carcinogenesis of breast cancer in premenopau-
sal women, gastric cancer, bladder cancer, esophageal
cancer, multiple myeloma, and non-Hodgkin lymphoma
may be more related to genome hypomethylation, while
the carcinogenesis of prostate cancer, colorectal cancer,
and acute lymphoblastic leukemia may be more related to
DNA synthesis. From the result of this meta-analysis, we
postulate that both DNA synthesis and genome methyla-
tion are involved in the hepatocarcinogenesis, and
genome hypomethylation may be more important.
Unfortunately, few studies in this meta-analysis had pro-
vided such environment factors and made further strati-
fied analysis impossible.
Some limitations of this meta-analysis should be
acknowledged. First, the number of studies included in
this article was insufficient and the sample size of individ-
ual studies was also small, leading to low statistical power.
Second, there were only European studies used CLD
patients as control subjects. So, the association needs to
be verified in other ethnicities. Third, there were few stud-
ies have examined the gene-gene and gene-environment
interactions, and so on.
Conclusion
In conclusion, this meta-analysis found some evidences of
the association between MTHFR C677T polymorphism
and HCC occurrence: MTHFR C677Tpolymorphism
increased the risk of HCC in a complete overdominant
model, suggesting it might be a risk factor for HCC, espe-
cially in European CLD patients. The association between
MTHFR C677T polymorphism and HCC warrants further
examination, especially in other ethnicities. Particularly,
researches including environment factors (such as folate
level, alcohol, smoking habits, hepatic virus B and C, etc.)
in a larger scale would be more effective.
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